Geriatrics

Fewer patients who received masitinib 4.5 mg/kg/day reached severe dementia stage.

Patients with any presence of small vessel disease had a 2-times greater risk of recurrent ischemic stroke than those without.

The agency is expected to rule on the Novartis treatment in 2021.

Researchers from USC propose a direct neurotoxic effect of particulate matter smaller than 2.5 μm.

After a sudden reversal and complex analyses, aducanumab’s future rests in the hands of the FDA while the community stands split on if the available data are enough to justify an approval.

Ongoing debates question whether or not lipid lowering in elderly patients offers similar clinical benefit as in younger patients.

Investigators find frailty is a key risk factor for age-related cognitive dysfunction and dementia.

There was very little difference found in visual acuity whether or not anti-VEGF treatments were used.

In data presented at AAO 2020, investigators test imaged guided intravitreal aflibercept injections for sight improvements.

In data presented at AAO, investigators find BI 836680 shows early signals of bioactivity.

The study authors noted that dementia prevention could become a compelling indication for older individuals receiving antihypertensive treatment.

Older patients benefit greater from LDL-cholesterol lowering medications.

Life expectancy rates were lower in patients with IBD when compared to a healthy control group.

The findings of this multicenter cohort may have implications for diagnosis, prognosis, and disease monitoring, as well as for clinical trials targeting disease-specific proteins in DLB.

A younger baseline age and more injections during the first year of treatment was linked to better long-term outcomes.

Venetoclax in combination with azacitidine was shown to prolong survival and increase chance of remission.

Cataracts, but not AMD or glaucoma, were associated with an increased risk of depressive symptoms in the elderly in a prospective long-term study.

ELP Pharma readying plans to continue to study the drug in a phase 3 trial.

History of syncope was present in 17% of the Parkinson group who had an altered blood pressure regulation upon standing and in 10% of those without.

SFChT in treatment-naïve eyes was positively associated with eGFR and diabetic retinopathy grade.

The treatment could also be used for Alzheimer disease and mid-stage Huntington disease for patients who suffer from greater cognitive deficits.

Those who slept more than 10 hours or less than 4 hours per night declined faster than those who slept about 7 hours per night.

Sumifilam could be the first Alzheimer treatment to improve several biomarkers.

Dr. Mali talks about advancements in treatment and screening for Wet AMD.

More than half of the eyes observed in the study displayed collapse of the associated druse or drusenoid PED.